Sara Coca Membribes· @scocmem · X·· 1 天前评分70
正文 · 原文
#ESMO26 Long-term EV-103 follow-up (up to 7 years) shows remarkable durability with ~30% of responders still in response at 7 years
The next step is identifying long-term responders through biomarkers (Nectin4?) and optimising treatment duration (ctDNA?)
@OncoAlert
224 浏览 · 6 赞 · 5 转发 · 0 回复
会议摘要
4740RO按 Rapid oral 1: Genitourinary tumours, renal and urothelial 对上
Enfortumab Vedotin (EV) With or Without Pembrolizumab (P) as First-Line (1L) Treatment for Cisplatin (cis)-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): Long-Term Follow-up Analysis from EV-103 Cohorts DE/A and K
https://esmocongress.esmo.org来源：Sara Coca Membribes · x.com